Presseportal.ch - Zhejiang Hisun Pharmaceutical Co. Ltdhttps://www.presseportal.ch/fr/nr/100076781?langid=2Presseportal.ch: Zhejiang Hisun Pharmaceutical Co. Ltd (Newsroom)fr-frnews aktuell schweiz AGhttps://www.presseportal.ch/images/logos/logo-ch-250.jpgPresseportal.ch - Zhejiang Hisun Pharmaceutical Co. Ltdhttps://www.presseportal.ch/fr/nr/100076781?langid=2info@newsaktuell.ch (presseportal.ch)Tue, 14 Apr 2026 10:42:20 +0200Mon, 22 Jun 2020 12:49:51 +0200Zhejiang Hisun Pharmaceutical Co. Ltd6Hisun Pharmaceutical: Free of COVID-19, Governments Suggest FavipiravirZhejiang Hisun Pharmaceutical Co. Ltd: Taizhou, China (ots/PRNewswire) - Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident ...https://www.presseportal.ch/fr/pm/100076781/100850350?langid=2Mon, 22 Jun 2020 12:49:51 +0200https://www.presseportal.ch/fr/pm/100076781/100850350?langid=2 Zhejiang Hisun Pharmaceutical Co. Ltd [Newsroom]
Taizhou, China (ots/PRNewswire) - Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident ... Lesen Sie hier weiter...

]]>Économieinfo@newsaktuell.ch (presseportal.ch)Zhejiang Hisun Pharmaceutical Co. Ltd